ZEON CORPORATION
1-6-2 Marunouchi, Chiyoda-ku, Tokyo 100-8246 Japan

January 5, 2026

Zeon Corporation

Zeon establishes Zeon BioSolutions, Inc. to expand its healthcare and life science business

Zeon Corporation (Zeon; head office: Chiyoda-ku, Tokyo; President and CEO: Tetsuya Toyoshima) has established a new company, Zeon BioSolutions, Inc. (Zeon BioSolutions).

Zeon is accelerating the creation of new business in the healthcare and life sciences field, which is positioned as one of the four growth areas*1 outlined in its STAGE30 medium-term management plan.

Zeon BioSolutions has acquired from Knowledge Palette, Inc. a business that uses Quartz-Seq2, the world's most accurate cell analysis technology*2, and will offer transcriptome analysis services. The acquisition is expected to generate synergies through the combination of this technology and Zeon assets such as its precision molding technology using Cyclo Olefin Polymers, thereby acceleratenge the creation of new business in the healthcare and life sciences field.

In Phase 3 of the STAGE30 medium-term management plan, Zeon aims to raise the sales ratio of the four growth areas to 48% of total sales by fiscal 2028 and, in particular to restructure its business portfolio by concentrating management resources in these four growth areas.

Zeon remains committed to advancing a sustainable Earth and a safe, comfortable life for people by contributing to a sustainable society and delivering technologies, products, and services that are indispensable.

Outline of Zeon BioSolutions

Company name	Zeon BioSolutions, Inc.
Address	1-5-5 Minatojima-minamimachi, Chuo-ku, Kobe City, Hyogo Prefecture, Japan
Business	Transcriptome analysis services
Date of establishment	October 2025
Representative	Chairman: Masahiro Nakamura, President and CEO: Katsuya Nishimura
Shareholder	Zeon Corporation: 100%

*1 Four growth areas: Mobility, Healthcare and Life Science, Telecommunications, and GX
*2 A high-throughput RNA sequencing method capable of measuring whole gene expression with high precision and low cost, even from a single cell (Reference: Sasagawa et al. Genome Biology 2018, Mereu et al. Nature Biotechnology 2020)

For more information, contact:
Department of Corporate Communications, Corporate Sustainability Division, Zeon Corporation Contact form